BullFrog AI To Unveil Scenario-Based Decision Engine For Pharmaceutical Portfolio Strategy And Clinical Trial Design; New Capabilities To Be Launched On March 25

BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW))) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence ("AI") and machine learning to turn complex biomedical data into actionable insights, announces the coming launch of a new scenario-based decision engine for pharmaceutical portfolio strategy and clinical trial design.

The new AI capability advances the Company's end-to-end intelligence workflow by adding a strategic decision layer on top of existing platforms bfPREP™ and bfLEAP®. Unlike traditional portfolio tools that collapse complex judgments into single scores and fixed weightings, the upcoming offering evaluates options using proprietary algorithms and methodologies revealing which programs are robust winners and which succeed only under narrow conditions.

Key capabilities include:

• Compares drug programs, indications, and trial designs without forcing arbitrary numerical scores
• Tests portfolio decisions against multiple explicit scenarios (e.g., capital-constrained, platform-building, US-first, global)
• Identifies options that perform well across strategic futures
• Preserves portfolio diversity while surfacing clear leaders to balance concentration with risk mitigation